Onconetix, Inc. (NASDAQ:ONCO) Short Interest Update

Onconetix, Inc. (NASDAQ:ONCO) was the recipient of a large decline in short interest in the month of January. As of January 30th, there was short interest totaling 107,197 shares, a decline of 13.9% from the January 15th total of 124,512 shares. Currently, 7.0% of the company’s shares are short sold. Based on an average daily trading volume, of 212,934 shares, the short-interest ratio is currently 0.5 days. Based on an average daily trading volume, of 212,934 shares, the short-interest ratio is currently 0.5 days. Currently, 7.0% of the company’s shares are short sold.

Onconetix Stock Performance

Shares of NASDAQ ONCO traded up $0.02 during trading on Tuesday, reaching $0.80. The stock had a trading volume of 214,599 shares, compared to its average volume of 343,825. The company has a market cap of $1.23 million, a P/E ratio of 0.07 and a beta of 3.45. Onconetix has a fifty-two week low of $0.62 and a fifty-two week high of $46.10. The business’s 50-day moving average price is $1.62 and its 200-day moving average price is $2.52.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Onconetix stock. Citadel Advisors LLC purchased a new stake in Onconetix, Inc. (NASDAQ:ONCO) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 15,633 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned 1.00% of Onconetix as of its most recent SEC filing. Institutional investors own 23.89% of the company’s stock.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.